Research Coverage of Japanese Listed Companies, Shared Research Inc

Shared Research

Research Coverage of Japanese Listed Companies

Shared Research Inc

Pioneering research coverage of Japanese listed companies. Now customizable and interactive for global institutional investors. Corporate access reimagined.

Equity Bottom-Up

<ul><li>Operating revenue increased to JPY2.4bn (+58.4% YoY), with a net loss of JPY340mn, driven by rising R&D expenses.</li><li>Royalty income from four products and tegoprazan expansion reached JPY1.5bn, with milestone payments contributing to revenue.</li><li>Operating expenses totaled JPY2.4bn (+49.5% YoY), including significant R&D costs, leading to an operating loss of JPY27mn.</li></ul>

Operating revenue increased to JPY2.4bn (+58.4% YoY), with a net loss of JPY340mn, driven by rising R&D expenses.Royalty income from four products and tegoprazan expansion reached JPY1.5bn, with milestone payments contributing to revenue.Operating expenses totaled JPY2.4bn (+49.5% YoY), including significant R&D costs, leading to an operating loss of JPY27mn.

Raqualia Pharma (4579 JP): Q3 FY12/24 flash update

<ul><li>Operating revenue increased to JPY1.4bn (+39.1% YoY), with an operating loss of JPY154mn and a recurring loss of JPY278mn.</li><li>Royalty income from four launched products and global expansion of tegoprazan generated JPY998mn (+36.3% YoY) in 1H FY12/24.</li><li>Total operating expenses rose to JPY1.6bn (+50.9% YoY), including R&D expenses of JPY833mn (+38.0% YoY) and SG&A expenses of JPY506mn (+62.1% YoY).</li></ul>

Operating revenue increased to JPY1.4bn (+39.1% YoY), with an operating loss of JPY154mn and a recurring loss of JPY278mn.Royalty income from four launched products and global expansion of tegoprazan generated JPY998mn (+36.3% YoY) in 1H FY12/24.Total operating expenses rose to JPY1.6bn (+50.9% YoY), including R&D expenses of JPY833mn (+38.0% YoY) and SG&A expenses of JPY506mn (+62.1% YoY).

Raqualia Pharma (4579 JP): 1H FY12/24 flash update

Japan

RaQualia Pharma, Inc. is a pharmaceutical company. The Company develops compounds for patient studies and sells drugs to pharmaceutical manufacturers. RaQualia also provides research on remedies in gastrointestinal, liver diseases, and pain in general areas.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Raqualia Pharma (4579 JP)